{"id":3071,"date":"2017-01-19T04:16:11","date_gmt":"2017-01-19T09:16:11","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=3071"},"modified":"2025-09-20T19:14:24","modified_gmt":"2025-09-21T01:14:24","slug":"cdc-report-pan-resistant-ndm-klebsiella-nevada-sad-tale","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/01\/19\/3071\/cdc-report-pan-resistant-ndm-klebsiella-nevada-sad-tale\/","title":{"rendered":"CDC Report on Pan-Resistant NDM Klebsiella in Nevada\u2013 A Sad Tale"},"content":{"rendered":"

\"\"<\/a><\/p>\n

During the past few weeks the case of a patient with MDR Klebsiella infection has made the news. We are told that this particular pathogen is \u201cresistant to 26 antibiotics\u201d. We were informed that the patient had multiple prior hospitalizations in India, supposedly the origin of the uncontrolled untreatable infection.<\/p>\n

CDC released a bit more information in MMWR on Jan. 13, 2017. The organism, an NDM-positive, mcr-1 negative K. pneumoniae isolate was described as resistant to colistin and aminoglycosides, and intermediate susceptible to tigecycline. However, the authors then goes on to tell us that the Klebsiella strain was only susceptible to fosfomycin, a drug \u201dapproved in the United States only as an oral treatment of uncomplicated cystitis; an intravenous formulation is available in other countries\u201d[1]<\/a>.<\/p>\n

\"\"<\/a><\/p>\n

The scenario is reminiscent of a case we described in an earlier blog<\/a> which details how difficult it can be\u00a0to import life-saving antibiotics into the USA. Even if these drugs are\u00a0approved elsewhere just not in the USA.<\/p>\n

We are informed by CDC that such pan-resistant strains are really rare and that it is important to obtain a travel history. \u00a0Hey, and don’t forget contact precautions and isolation procedures, please!<\/p>\n

The MMWR note says nothing about therapeutic options or how to obtain fosfomycin IV. \u00a0How\u00a0ironic, almost cynical, you may say.<\/p>\n

This kind of advice reminds us of medical practice in the Middle Ages when doctors believed in the miasma theory of infection and therefore advised patients to leave populated areas and head for the countryside to avoid the plague. Those with the disease were left behind to die. Appropriate advice in times when there were no antibiotics, no doubt. Now we have CDC doing pretty much the same.<\/p>\n

The \u2018abysmal state of sanitation\u2019 in rural India is hard to imagine: households have cellphones and TVs but do not have toilets [2]<\/a>\u00a0 This is a set-up for disease transmission and a haven for bacterial recombination, made worse by a dismal public health record to ensure even the most basic hygienic standards<\/span><\/p>\n<\/div>\n

Frankly, we would have expected more practical advice from the CDC. Why not – as we proposed earlier – make fosfomycin IV more easily available from a European source? Or stockpile it under the aegis of CDC for quick retrieval? Here are some other thoughts \/ alternatives:<\/p>\n

    \n
  1. Obtain fosfomycin on a compassionate use basis from Zavante Therapeutics, which is a US company working on a submission for fosfomycin IV (ZTI-01)?<\/li>\n
  2. Use the veterinary formulation of the drug. Fosfomycin IV has been used for over 40 years in livestock\u00a0[3]<\/a>, but the drug is not listed in the Green Book of Approved Veterinary Drugs issued by the FDA\u00a0[4]<\/a>.\u00a0However, fosfomycin and all its formulations are approved in Canada\u00a0[5]<\/a> and, of course, south of the border.<\/li>\n
  3. Obtain an experimental drug undergoing development. FDA, CDC or BARDA have susceptibility information on novel drugs in the pipeline, that is not yet in the public domain and could help in such a dire case.
    \nClearly, the K. pneumoniae strain was resistant to aminoglycosides but we have not heard whether plazomicin was tested as well, a drug now in Phase 3. How about eravacycline or omadacycline, some newer tetracyclines with better PK than tigecycline? There are other NCEs or combinations of drugs (see the Spero line-up) which could be considered in a desperate situation.<\/li>\n
  4. If all else fails, should one simply buy the drug from Sigma-Aldrich? Their laboratory-grade fosfomycin should be good enough\u00a0[6]<\/a>, but talk to your institutional Ethics Committee first before you go this route. The lawyers are lurking.<\/li>\n<\/ol>\n

    None of this happened for the patient in the MMWR report \u2013 she was treated with vancomycin, Zosyn, Unasyn, aztreonam, ertapenem, meropenem, and polymyxin B, all drugs with documented ineffectiveness.<\/p>\n

    If Obama or Trump or Gates had an MDR\u00a0infection like this, would exceptions be made and fosfomycin IV be flown in from the outside?\u00a0 You bet!
    \nChurchill was treated with an \u2018experimental\u2019 sulfonamide when he came down with pneumonia in 1943.<\/span><\/p>\n<\/div> Fosfomycin is not just any drug; recent susceptibility data support the use of fosfomycin in colistin-resistant E. coli     [7]<\/a>. Fosfomycin is also on the WHO List of critically important drugs\u00a0[8]<\/a>. Why, then, is it that we cannot bring it\u00a0to the US for a patient in need!<\/p>\n

    We recognize that a severely infected sick patient cannot easily be transported from the US to another country which has a more liberal drug importation philosophy. Maybe patients with MDR infections should not return to the US and instead head for Canada, Europe or Mexico.<\/p>\n

    It is not enough for\u00a0CDC to tells us to wash hands and not spread bad germs. Testing for the mcr-1 gene and informing us of its absence in that isolate is pure academics and in no way helps us manage these infections.<\/p>\n

    We need more flexible and innovative approaches. None of this was offered\u00a0in the CDC notification which showed zero compassion. Very disappointing!\u00a0 Very bureaucratic!\u00a0 Very sad!<\/p>\n

    We need to become AIDS activists again and fight back against an inveterate system.<\/p>\n

    <\/a>
    “If I cannot deflect the will of heaven, then I shall move hell”<\/figcaption><\/figure>\n

    References:
    \n<\/strong>    [1]<\/a> L Chen. Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae \u2014 Washoe County, Nevada, 2016. MMWR Morb Mortal Wkly Rep 2017;66:33.
    \n    [2]<\/a> S Nayyar. https:\/\/www.healthissuesindia.com\/2014\/02\/05\/sanitation-health-hygiene-india\/
    \n    [3]<\/a> D Perez.\u00a0 Fosfomycin: Uses and potentialities in veterinary medicine.\u00a0 Open Veterinary Journal 2014; 4: 26
    \n    [4]<\/a> http:\/\/www.fda.gov\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/default.htm
    \n    [5]<\/a> http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/pdl-ord\/pdl_list_fin_ord-eng.php#a2
    \n    [6]<\/a> http:\/\/www.sigmaaldrich.com\/catalog\/search?term=fosfomycin&interface=All&N=0&mode=match%20partialmax&lang=en&region=JO&focus=product
    \n    [7]<\/a> M Castanheira. Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. AAC 2016; 60:5623
    \n    [8]<\/a> WHO Critically important antimicrobials for human medicine \u2013 4th rev. 2016; http:\/\/apps.who.int\/iris\/bitstream\/10665\/251715\/1\/9789241511469-eng.pdf?ua=1<\/p>\n","protected":false},"excerpt":{"rendered":"

    During the past few weeks the case of a patient with MDR Klebsiella infection has made the news. We are told that this particular pathogen is \u201cresistant to 26 antibiotics\u201d. We were informed that the patient had multiple prior hospitalizations in India, supposedly the origin of the uncontrolled untreatable infection. Continue reading CDC Report on Pan-Resistant NDM Klebsiella in Nevada\u2013 A Sad Tale<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[172,1909,1271,176,403,1906,1715,639,1910,163,1591,1903,1897,425,5,1896,1583,1901,1900,181,1912,1902,817,592,1899,433,170,1907,1904,1911,141,43,426,1913,1905,48,1908,961,1776,1898],"class_list":["post-3071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-achaogen","tag-aids-activism","tag-allphase-pharma-consulting","tag-aminoglycoside","tag-antibiotic-blog","tag-approved-veterinary-drugs","tag-barda","tag-cdc","tag-centers-for-disease-control-and-prevention","tag-churchill","tag-colistin-resistance","tag-compassionate-use","tag-drug-availability-in-usa","tag-eravacycline","tag-fda","tag-fosfomycin-iv","tag-harald-reinhart","tag-india-and-lack-of-hygiene","tag-mcr-1-gene","tag-mdr","tag-miasma","tag-mmwr","tag-multi-drug-resistant","tag-nce","tag-ndm-klebsiella-pneumoniae","tag-omadacycline","tag-plazomicin","tag-polymyxin-b","tag-spero-therapeutics","tag-stockpiling-antibiotics","tag-sulfonamide","tag-tigecycline","tag-tygacil","tag-unasyn","tag-usa-approved-antibiotics","tag-vancomycin","tag-who-list-of-critically-important-antibiotics","tag-zavante-therapeutics","tag-zosyn","tag-zti-01"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/CDC-KP-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Nx","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":3100,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/24\/3100\/kill-mocking-bug-cre-crab-variety\/","url_meta":{"origin":3071,"position":0},"title":"To Kill A Mocking Bug – of the CRKP or CRAB Variety","author":"Harald","date":"January 24, 2017","format":false,"excerpt":"Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times \u2013 or both - to improve T>MIC for the\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2313,"url":"https:\/\/allphasepharma.com\/dir\/2016\/03\/03\/2313\/iv-fosfomycin-to-the-rescue-and-to-a-place-near-you\/","url_meta":{"origin":3071,"position":1},"title":"IV Fosfomycin To The Rescue \u2013 And To a Place Near You","author":"Harald","date":"March 3, 2016","format":false,"excerpt":"A recent letter to the Editor by Simkins et al. is worth reviewing [1]. The authors describe the complicated course of a patient who suffered graft rejection after liver transplantation, received broad-spectrum antibiotics during prolonged hospitalization and eventually had a bloodstream infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) which was resistant\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Fosfomycin - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":445,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/02\/445\/why-the-next-novel-antibiotic-will-cost-40k-or-more\/","url_meta":{"origin":3071,"position":2},"title":"Why The Next Novel Antibiotic Will Be A Blockbuster And Cost $40k","author":"Harald","date":"July 2, 2014","format":false,"excerpt":"Looking at all antibiotics in the pipeline, I can\u2019t help but think that \u2013 by 2018 \u2013 there\u00a0will be\u00a0some blockbuster anti-infectives coming to the market. Why do I say this?\u00a0 What is going to generate this revenue stream for companies when the new crop of drugs will be restricted by\u2026","rel":"","context":"In "The Viewpoint"","block_context":{"text":"The Viewpoint","link":"https:\/\/allphasepharma.com\/dir\/category\/the_viewpoint\/"},"img":{"alt_text":"pills","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/pills-300x225.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1332,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/28\/1332\/drugs-with-qidp-designation-update-3282015\/","url_meta":{"origin":3071,"position":3},"title":"Drugs with QIDP Designation \u2013 Update 4\/8\/2015","author":"Harald","date":"March 28, 2015","format":false,"excerpt":"For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.\u00a0 They are listed in the Table below (if I missed a compound, please leave a comment!!). \u00a0The\u00a0table is searchable so you should be able to massage the data to\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"APPC + QIDP copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":3071,"position":4},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2186,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/19\/2186\/aztreonam-plus-avibactam-a-new-bright-star-in-the-night-sky\/","url_meta":{"origin":3071,"position":5},"title":"Aztreonam PLUS Avibactam \u2013 A New Bright Star in the Night Sky","author":"Harald","date":"December 19, 2015","format":false,"excerpt":"Looking at the molecular structure of ceftazidime (CTAZ) and aztreonam (ATM), the differences are clear, and so are the similarities: ATM does not have the cephem ring structure of CTAZ, only the 4-member beta-lactam ring.\u00a0 However, the side chains are identical in both CTAZ and ATM which explains the overlapping\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Avibactam - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=3071"}],"version-history":[{"count":17,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3071\/revisions"}],"predecessor-version":[{"id":3083,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3071\/revisions\/3083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/3073"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=3071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=3071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=3071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}